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1. INTRODUCTION 
The relationship between malignancy and thrombosis is known for over 
manyyears[1]. In almost half of the cancer patients, thromboembolism is 
present,which is detected at autopsy. Thrombosis in cancer often is migratory, 
may involve superficial veins and relatively unusual sites. The hypercoagulable 
state in malignancy is due to a complex interaction of tumor cells and their 
products with the host cells, leading to various degrees of impairment of the 
normal defense mechanisms that ordinarily protect the host against 
thrombogenesis[2]. Tumor cells  activate directly the blood clotting cascade and 
cause thrombosis or can induce procoagulant environment  and inhibit the 
anticoagulant properties of the vascular endothelial cells, platelets, monocytes 
and Macrophages.[1] 
There is evidence that the components of the coagulation/ fibrinolytic 
system play an important role in cancer biology and angiogenesis. Fibrin 
deposition and remodeling in extracellular matrix of the tumor is an important 
initial step in tumor metastasis. For a tumor to successfully metastasize from its 
primary location, it must undergo several obligate steps, including the invasion 
into either the lymphatic or vascular lumen, transportation through the 
circulation, and establishment of viability in target tissues. Cross linked fibrin in 
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the extracellular matrix serves as a stable framework for endothelialcell 
migration during angiogenesis and tumor cell migrationduring invasion.  
 Various abnormalities, including thrombocytosis, an increase in 
fibrinogen and fibrin degradation products like D-dimer, a rise in factors 
V,VII,VIII , IX, and XI levels, and a decrease in antithrombin III , are seen in 
cancer patients[3]. 
D-dimer (or D dimer) is a fibrin degradation product (or FDP), a small 
protein fragment present in the blood after a blood clot is degraded by 
fibrinolysis. It is so named because it contains two D fragments of the fibrin 
protein joined by a cross-link. The cross-link between two D fragments remains 
intact, however, and these are exposed on the surface when the fibrin fragments 
are sufficiently digested. The structure of D-dimer is either a 180 kDa or 195 
kDa molecule of two D domains, or a 340 kDa molecule of two D domains and 
one E domain of the original fibrinogen molecule. 
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D-dimers are not normally present in human blood plasma, except when 
the coagulation system has been activated, for instance because of the presence 
of thrombosis or disseminated intravascular coagulation. The D-dimer assay 
depends on the binding of a monoclonal antibody to a particular epitope on the 
D-dimer fragment. D-Dimer is detected by various laboratory methods, mostly 
used is based on a different monoclonal antibody against D-dimer. The binding 
of the antibody is then measured quantitatively by one of various laboratory 
methods. 
Breast cancer is the most common cancer in women causing death.  
The three most important prognostic factors in operable carcinoma breast 
are lymph node status, primary tumor size, and tumor grade.   
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Plasma D-dimer is a hypercoagulability and fibrinolytic system marker and is 
increased in patients with various solid tumors. 
It has been indicated that an interaction between angiogenesis and 
hemostasis may facilitate metastasis in breast cancer and that plasma D-dimer 
levels are a measurement of matrix remodeling in the tumor[4]. Elevated levels 
of circulating D-dimer have been correlated with an enhanced progression of the 
disease and a reduced overall survival in metastatic breast cancer[5]. D-dimer 
assessment constitutes a  attempt to consider a product of fibrin degradation as a 
specific marker related to the extent of  breast cancer in humans. 
 Several studies has been done to prove this finding, correlating 
fibrinolytic activity associated with increased D-dimer levels cancer breast 
patients.[6] 
 
 6 
 
 
Vascular endothelial cells injury caused by toxins released from fast 
growing tumor cells and the fibrinolytic activation on the surface of tumor cells, 
cancer patients often exhibit abnormalities in coagulation and fibrinolytic 
activities and their D-dimer levels tends to be higherthan those in non-neoplastic 
populations.[1] 
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2. AIMS AND OBJECTIVES 
 
• To evaluate pre-operative D-dimer level in Operable Carcinoma of Breast 
and post operative histopathology report for lymphovascular involvement. 
 
• To evaluate role of D-dimer in patients of operable carcinoma breast, in 
predicting lymph node metastasis in carcinoma patients and to look for 
relationship of these markers with histopathologic parameters which are 
known to have prognostic value in carcinoma breast. 
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3.HISTORTICAL BACKGROUND 
Humans have been known about Cancer of the breast for a long time. The 
medical text of Edwin Smith Surgical Papyrus which describes cases of breast 
cancer, dates back to 3,000–2,500 B.C.E. 
People made offerings in the shape of a breast to the god of medicine; in 
Ancient GreeceAnd Hippocrates in early 400s B.C.E described the stages of 
breast cancer. 
Around first century A.D., doctors experimented with surgical incisions 
made over the breast to destroy tumors, and thought that breast cancer was 
associated with the end of menstruation. This theory might have prompted the 
association of cancer with older age. 
In the beginning of the Middle Ages, medical progress was associated 
with religious philosophies. Christians thought surgery was barbaric and were in 
favor of faith healing. Meanwhile, Islamic doctors reviewed Greek medical texts 
to learn more about the breast cancer. 
The Renaissance saw a revival of surgery as doctors began exploring the 
human body. John Hunter is known as the Scottish father of investigative 
surgery, identified lymph as a cause of breast cancer. 
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 Lymph is the fluid which carries white blood cells throughout the body. 
Lumpectomies were also performed by surgeons, but there was no anesthesia 
yet. So, Surgeons had to be fast and accurate to be successful. 
The modern approach to breast cancer treatment and research started 
forming in the 19th century. 
1882: William Halsted performed the first radical mastectomy. This 
surgery was the standard operation to treat breast cancer until into the 20th 
century. 
1895: The first X-ray was taken. Eventually, low-dose X-rays called 
mammograms were used to detect breast cancer. 
1898: Marie and Pierre Curie discovered radium and polonium. Initially, 
radium was used in cancer treatment. 
1932: Modified Radical Mastectomy was developed. This surgical 
procedure was not as disfiguring as radical mastectomy and becomes the new 
standard. 
1937: Radiation therapy is used in addition to surgery to spare the breast. 
After removing the tumor, needles with radium are placed in the breast and near 
lymph nodes. 
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1978: The drug tamoxifen was approved by the Food and Drug 
Administration (FDA) for use in breast cancer treatment. Tamoxifen is an 
antiestrogen drug originally developed for birth control. It’s the first in a new 
class of drugs called selective estrogen receptor modulators (SERMs) used 
against cancer. 
1984: Researchers discovered a new gene in rats. The human version, 
called HER2, was found to be linked with more aggressive breast cancer when 
overexpressed. This cancer is called HER2-positive breast cancer and is not as 
responsive to treatments. 
1985: Researchers discover that women with early-stage breast cancer 
who were treated with a lumpectomy and radiation have similar survival rates to 
women treated with only a mastectomy. 
1986: How to clone the HER2 gene was discovered. 
1995: Cloning the tumor suppressor genes BRCA1 and BRCA2. Inherited 
mutations in these genes can predict an increased risk of breast cancer. 
1996: FDA approved Anastrozole as a treatment for breast cancer. This 
drug blocks the production of estrogen. 
 13 
 
1998: Tamoxifen is found to decrease the risk of developing breast cancer 
in at-risk women by 50 percent, approved by the FDA, it is used as a preventive 
therapy. Trastuzumab, a drug used to target cancer cells over-producing HER2, 
is also approved by the FDA. 
2006: The drug raloxifene foundto reduce breast cancer risk in 
postmenopausal women who are at higher risk. It has lower chance of serious 
side effects when compared with tamoxifen. 
SURGICAL ANATOMY 
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The breast is a skin appendage which develops from modified sweat 
glands deep to the nipple. Accessory breast tissue may occur along a line from 
groin to axilla. The development of the rudimentary breast is stimulated by 
hormones, and commences as a nodule or breast bud deep to the areola in early 
puberty. The adult breast lies predominantly on the deep fascia of pectoralis 
major and extends from the second to the sixth costal cartilages. Medially, it 
extends almost to the midline and laterally it continues as the axillary tail of the 
breast over the lateral edge of pectoralis major into the axilla. 
Superficially, it is separated from the skin by subcutaneousfat, except over 
the areola and the nipple. The breast substance consists of glandular tissue and 
surrounding fat. Alterations in hormonal levels cause structural and 
functionalchanges in the breast during pregnancy, lactation and, to a lesser 
extent, throughout the menstrual cycle. 
The blood supply of the breast :branches of the internal thoracic 
(mammary) artery and the intercostal arteries which pierce the intercostal 
muscles, and laterally from branches of the lateral thoracic artery. 
 The lymphaticdrainage of the breast follows all these routes, but the 
predominantdrainage is to the axillary lymph nodes. There issignificant drainage 
to the internal thoracic nodes from the medial breast. 
 THE AXILLA: 
The axillary contents are the fat and lymph nodes bounded by t
walls. The medial wall is bounded by the chest wall covered with serratus 
anterior. The anterior wall of the axilla is formed by the pectoral muscles and 
the clavipectoralfascia.
and subscapularis 
.
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 The posterior wall comprises latissimusdorsi, teres major 
 
 
he axillary 
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LYMPHATIC DRAINAGE OF THE BREAST: 
The axillary lymph nodes lie in the fat of the axilla and receive lymphatic 
drainage from the upper limb and the superficial tissue of the chest wall in 
addition to the breast. Lymphatic channels from the breast drain predominantly 
first to the nodes lowest in the axilla, and then subsequently to the higher nodes, 
and finally through the apex of the axilla to the supraclavicular nodes. 
 The axillary nodes are arbitrarily divided into levels I, II and III 
dependent upon their relationship to the pectoralis minor muscle. Level I nodes 
are lateral and below the muscle, level II nodes are behind it, and level III nodes 
are above and medial. 
As in malignant melanoma , there is increasing appreciation that the 
lymph node drainage of the breast is first to one or more specific nodes called 
sentinel nodes. These are usually in the axilla but they can be in the internal 
thoracic chain or, more rarely, within the breast itself. 
 17 
 
 
Level 1-Lateral to lateral border of pectoralis minor 
• Anterior (Pectoral) 
• Posterior (Subscapular) 
• Lateral (Brachial) 
Level 2-Behind pectoralis minor 
• Central 
• Rotters 
Level 3-Medial to medial border of pectoralis minor 
• Apical (Infraclavicular) 
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EPIDEMIOLOGY: 
 
Breast cancer continues to be the leading cause of cancer in women,by 
causing 40,000 deaths annually. Morethan 1 million cases of breast cancer 
diagnosed worldwide each year, making Breast Carcinoma a global health 
problem. The overall incidence of breast cancer was rising until approximately 
1999 because of increases in the average life span, lifestyle changes that 
increase the risk for breast cancer, and improved survival from other diseases. 
The rates began to decrease from 1999 to 2006 by approximately 2%/year. This 
decrease has been attributed to a reduction in the use of HRT after the initial 
results of the Women’s Health Initiative were published but may also be  the 
result of   screening mammography . 
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70.1% of women 40 years and older were screened in 2000 versus 66.4% 
in 2005. Survival rates in women with breast cancer have steadily improved 
over the last several decades, with 5-year survival rates of 63% in the early 
1960s, 75% from 1975 to 1977, 79% from 1984 to 1986 and 90% from 1995 to 
2005. The largest decrease in death rates caused by breast cancer have been in 
women younger than 50 years (3.2%/year), although they have also decreased in 
women older than 50 (2%/year). 
 The decreased mortality from breastcancer is thought to be the result of 
earlier detection via mammographicscreening, improvements in therapy, and a 
decreased incidence of breast cancer.  
 The current treatment of breast 
and recent insights intobreast cancer biology. There is an
defining disease biology and status in individual patients, with t
tailoring of therapies toward that individual.
RISK FACTORS OF CARCINOMA BREAST:
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cancer is guided by pathology, staging, 
 increased emphasis on 
 
 
he subsequent 
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PATHOLOGY 
 
Noninvasive Breast Carcinoma: 
Noninvasive neoplasms divided into two major types, LCIS and DCIS . 
LCIS was initially believed to be a malignant lesion, but is now regarded 
more as a risk factor for the development of breast cancer. LCIS is recognized 
by its conformity to the outline of the normal lobule, with expanded and filled 
acini. DCIS is a more heterogeneous lesion morphologically, and pathologists 
 recognize four broad categories
DCIS is recognized as discrete spaces filled with malignant cells, usually with a 
recognizable basal cell layer made up
The four morphologic categories of DCIS are rarely seen as pure lesions, but in 
reality are often mixed. The papillary and cribriform types of DCIS are 
generally of lower grade and may take a longer period of time
invasive cancer. The solid and comedo types of DCIS are generally higher grade 
lesions. 
INVASIVE  DUCTAL CARCINOMA:
Invasive ductal cancer, al
most common form of breast cancer; it account
breast cancers. When this carcinomadoes not have any specific 
called infiltrating ductal 
to 10% of breast cancers, and mixed 
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—papillary, cribriform, solid, and comedotypes. 
 of presumably normal myoepithelial cells. 
 
 
so known as infiltrating ductal 
s for 50% to 70% of invasive 
carcinoma. Invasive lobular carcinoma accounts for up 
ductal and lobular cancers have 
 to transform to 
carcinoma, is the 
features, it is 
been 
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increasingly recognized and described in pathology reports. When infiltrating 
ductal carcinomas take on differentiated features, they are named according to 
the features that they display. 
If the infiltrating cells form small glands lined by a single row of bland 
epithelium, they are called infiltrating tubular carcinoma. The infiltrating cells 
may secrete copious amounts of mucin and appear to float in this material. 
These lesions are called mucinous or colloid tumors. Both tubular and mucinous 
tumors are usually low grade (gradeI) lesions and represent about 2% or 3% 
each of invasive breast carcinomas. 
The different histologic subtypes of breast cancer have some relationship 
with prognosis, although this is influenced by tumor size, histologic grade[7], 
hormone receptor status, HER-2 status, lymph node status, and other prognostic 
variables [8]. Infiltrating ductal carcinoma, not otherwise specified (NOS), is the 
most common form of breast cancer. Its prognosis is variable, modified by 
histologic grade and expression of molecularmarkers. Basal-like cancer, or 
medullary cancer in older classifications, is commonly an aggressive form of 
breast cancer and, because it is triple receptor–negative, there are no targeted 
treatmentsfor this form of cancer. Infiltrating lobular breast cancers carry an 
intermediate prognosis, whereas tubular and mucinous cancers have the best 
overall prognosis. 
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Molecular Markers and Breast Cancer Subtypes: 
 
Estrogen receptors and progesterone receptors may be found in breast 
cancer cells. Cancer cells with these receptors depend on estrogen and related 
hormones, such as progesterone, to grow. Estrogen and progesterone influence 
many hormonal functions in women, such as breast development. IHC testing 
can detect estrogen and progesterone receptors in cancer cells from a sample of 
tissue.[10] 
HER2 is a member of the human epidermal growth factor receptor 
(HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene 
has been shown to play an important role in the development and progression of 
certain aggressive types of breast cancer[9] 
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HER2 is the target of the monoclonal antibody trastuzumab (marketed as 
Herceptin). Trastuzumab is effective only in cancers where HER2 is over-
expressed. One year of trastuzumab therapy is recommended for all patients 
with HER2-positive breast cancer who are also receiving chemotherapy.An 
important downstream effect of trastuzumab binding to HER2 is an increase in 
p27, a protein that halts cell proliferation.Another monoclonal antibody, 
Pertuzumab, which inhibits dimerisation of HER2 and HER3 receptors, 
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CLINICAL FEATURES: 
 
Although any portion of the breast, including the axillary tail, may be involved, 
breast cancer is found most frequently in the upper outer quadrant. 
• Hard lump, which may be associated with indrawingof the nipple. 
•  As the disease advances locally there may be skin involvement with 
peaud’orange or frankulceration and fixation to the chest wall. This is 
described as cancer-en-cuirasse when the disease progresses around the 
chest wall. 
• Axillary lymphadenopathy 
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• Signs and symptoms of metastasis 
 
 
1. Opposite axilla and opposite breast 
2. Abdominal examination for secondaries in the liver whichpresent as nodular 
liver, ascites and Krukenberg’stumourbilateralbulky ovarian metastasis. 
3. Rectal examination to rule out deposits in rectouterinepouch 
4. Respiratory system examination to rule out effusion. 
5. Bony tenderness should be looked for in the spine, longbones, skull, etc. 
 
 
  
STAGING OF CARCINOM
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A BREAST: 
 
 Breast cancer stage is done 
(clinical staging) and on definitive surgical treatment by pathologic examination 
of the primary tumor and regional lymph nodes (pathologic 
 
29 
with physical examination,
staging). 
 
 imaging studies 
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Breast cancer is staged according to the TNM classification system, which 
groups patients into four stage groupings based on the size of the primary tumor 
(T), status of the regional lymph nodes (N), and presence or absence of distant 
metastasis (M). The most commonly used system is of American Joint 
Committee on Cancer (AJCC). This system is updated every 6 to 8 years to 
reflect current understanding of tumor behavior. 
  INVESTIGATIONS AND MANAGEMENT
BLOOD INVESTIGATIONS:
• Complete blood Count
anemia. 
• Liver function test: increased ALP suggests bone or liver metastasis,
• D-dimer can be considered as a potential prognostic marker as shown in 
various studies. 
INVESTIGATIONS FOR DIAGNOSIS:
• Mammogram and ultra sound of breast with axilla:
Normal Mammogram 
Used as a Screening test forAsymptomatic women of more than 40 years.
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: Hb% may be decreased due to ca
 
 
rcinoma/ 
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 Used as Diagnostic :Women with pain in the breast, mass,discharge, clinical 
features suggestive of malignancy. 
Mediolateral oblique view is for outer quadrant and axilla and Craniocaudal 
view is for medial quadrants. Radiation dose is 0.1 centigray (cGy). 
 Benign lesions like fibroadenoma shows round, punctate, popcorn like. 
 
Mammogram-fibroadenoma 
 Highly suspicious—pleomorphic, heterogenous Solid mass with irregular edges 
speculation,Long tentacles—Tentaculation, Fine scattered calcification—
Microcalcification, Distortion of architectural pattern of the breast. 
Asymmetrical thickening of breast tissues. 
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Carcinoma breast Mammogram with irregular edges 
ULTRASOUND OF BILATERAL BREAST AND AXILLA: 
 
Ultrasound image of breast cancer. 
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The mass is solid, contains internal echoes, and displays an irregular 
border. Most malignant lesions are taller than they are wide. 
Ultrasonography is useful in determining whether a lesion detected by 
mammography is solid or cystic. Ultrasonography can be useful for 
discriminating lesions in the patient with dense breasts. However, it has not been 
found to be a useful screening tool because it is highly dependent on the 
operator performing the freehand screening and there is a lack of standardized 
screening protocols.  
 
The American College of Radiology Imaging Network (ACRIN) has 
performed a trial (ACRIN 6666) inhigh-risk women in whom mammography 
and ultrasonographywere performed in randomized order to compare the 
sensitivity, specificity, and diagnostic yield of ultrasonography plus 
mammography compared with mammography alone.  
 The investigators found that the combination of ultrasonography and 
mammography allowed for an increased diagn
women. Ultra sonogram of the contralateral breast to rule out bilateral breast 
disease and ultra-sonogram of the axilla to rule out axillary lymphadenopathy.
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ostic yield of 4.2cancers/1000 
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Fine Needle Aspiration Cytology 
Fine-needle aspiration (FNA) biopsy is a common tool used in the 
diagnosis of breast masses. It can be done with a 22-gaugeneedle, an 
appropriate-sized syringe, and an alcohol preparationpad. The aspirate must be 
properly prepared on a slide for cytologicexamination to be clinically useful. 
The main usefulness ofFNAC is differentiation of solid from cystic masses, but 
itmay be performed whenever a new, dominant, unexplained massis found in the 
breast. 
 
Most clinicians recommend core needle biopsy for definitive histologic 
diagnosis prior to surgical intervention.  
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A positive result on FNA biopsy allows the surgeon to begin informed 
discussions with the patient; however, definite plans for treatment should be 
based on the histologic diagnosis from a Core Needle Biopsy. 
• CORE NEEDLE BIOSPY 
This technique is preferred for the diagnosis of palpable lesions, as 
core needle biopsy provides hormonal status of the tumor, for treatment of 
the disease. 
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In case of non- palpable lesions: 
Biopsy can be performed under mammographic (stereotactic), 
Ultrasonography  guidance, or Magnetic resonance imaging (MRI) guidance. 
Mass lesions that are visualized on ultrasonography can be sampled under 
ultrasonography guidance; calcifications and densities that are best seen on 
mammography are sampled under stereotactic guidance. 
During stereotactic core needle biopsy, the breast is compressed, most 
often with the patient lying prone on the stereotactic core biopsy table. 
A robotic arm and biopsy device are positioned by computed analysis of 
triangulated mammographic images. After local anesthetic is injected, a small 
skin incision is made and an 11-gauge core biopsy needle is inserted into the 
lesion to obtain the tissue sample. 
 39 
 
 
Mammotome: 
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It is a hand held vacuum-assisted biopsy instrument which can be used 
under image (ultrasound or stereotactic) guidance. It gives accurate diagnosis of 
no palpable mammographic abnormalities. 
Role of MRI in Carcinoma Breast: 
 
• Particularly useful in detecting malignancy when mammographically subtle or 
occult (lobular carcinoma). 
• It can differentiate scar tissue from cancer. Hence can detect local recurrence 
after surgery. 
• MRI is better than mammogram in assessing the response of the tumour to 
neoadjuvant chemotherapy. 
• It is also better investigation in dense breasts and in pregnancy. 
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• Also for imaging of the breast with implants. 
Unknown primary with axillary nodes are positive for adenocarcinoma. MRI is 
the ideal investigation to detect a impalpable breast lump. 
‘TRIPLE ASSESSMENT’  
• History and clinical examination 
• Imaging : Ultrasound/Mammogram 
• Fine Needle Aspiration Cytology/Core Needle Biopsy 
Early Breast Carcinoma EBC (Stage I and Stage II) Staging work up: 
• Chest X-ray: Rule out pulmonary secondaries/ pleural effusion  
             - Cannon ball type :Presents late 
             - Lymphangiectatictype: Presentswith intractable cough. 
• Abdominal ultrasonography done to rule out liver metastasis, 
hepatomegaly, ascites, rectovaginal deposits. 
• Xray of long bones, whole spine with pelvis, cranium: to rule out bone 
metastasis. 
 Locally Advanced Breast Carcinoma and Advanced Breast Carcinoma (Stage 
III and Stage IV) 
 • Contrast Enhanced Computer Tomography Chest( CECT chest) to rule 
out lung metastasis, pleural effusion, mediastinal widening.
• Contrast Enhanced Computer Tom
out liver metastasis, ascites, rectal deposits, as the stage of the tumor 
increases there is increased incidence of systemic metastasis which cannot 
be picked up by  Xrays of chest and long bones, whole spine and cranium
and USG Abdomen and pelvis 
• Bone scan: rule out bone metasta
• Treatment of early breast cancer
 
 
 
42 
ography Abdomen and pelvis: to rule 
 
sis 
—Stage I, IIA 
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A. Primary 
• Locoregional control of primary disease is by surgery in the form of Modified 
radical mastectomy (MRM) or Breast conservative surgery (BCS). 
B. Adjuvant 
• Loco regional control of residual disease is by radiotherapy 
• Systemic control of disease is by Hormonal therapy or Chemotherapy. 
SURGERY: 
1. Wide local excision (lumpectomy) is indicated in tumorsless than 4 cm 
in size and with well differentiated histology. It includes removal of the tumor 
with a rim of at least 1 cm of normal breast tissue. If the nodes are palpable and 
enlarged, this is combined with axillary block dissection, using separate 
incision. Currently, this procedure has become more popular. It is also called as 
Breast Conservative Surgery.  Radiotherapy to the breast tissue is mandatory in 
all cases of breast conservation surgery. 
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BREAST CONSERVATIVE SURGERY: 
 
• Involves the following three steps apart from removal of cancer alone: 
1. Removal of tumor with wide margin 
2. Adjuvant radiotherapy 
3. With or without assessment of axillary lymph node status. 
Indications: 
• Solitary cancer 
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• Possible to excise the tumor with tumor free margins without disrupting the 
breast cosmetically 
• No contraindications to RT (e.g. pregnancy, collagen vascular disorders which 
may exaggerate the reaction and prior RT to same breast) 
• Well motivated patient. 
Contraindications: 
• Presence of two or more primary tumors in separate areas of breast 
• Diffuse malignant appearing calcification 
• History of prior radiation to breast (will be a contraindication for full breast 
radiation) 
• Pregnancy (1st and 2nd trimester) can be done in third trimester. 
• Collagen vascular disorders where RT cannot be given (RT exaggerates the 
disorder) 
• Large tumor in a small breast that does not respond to induction chemotherapy 
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SENTINEL NODE BIOPSY 
Sentinel node: 1st node to drain the tumor. 
 
Two methods: 
• On the day prior to surgery, the radioactive colloid (Technetium 99m 
sulfur or radioalbumin) is injected using a tuberculin syringe into three to 
four separate sites at the cancer area or subdermally proximal to cancer; 
the node biopsied using hand-held gamma camera peroperatively. 
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During surgery patent blue dye (methylene blue) is injected into the tumor 
and the sentinel node identified and sent for frozen section biopsy. 
If sentinel node biopsy is positive for malignancy, can procedure with 
axillary node dissection with separate axillary incision, followed by 
radiotherapy.2.Modified Radical Mastectomy (MRM) is equally good (good 
retraction of pectoralis minorfacilitates axillary dissection - Auchincloss 
modification. 
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Advantages of Modified Radical  Mastectomy over Halsted radical mastectomy: 
• Cosmetically better accepted as axillary fold is maintained. 
• Function of the shoulder is better, and it gives a stronger and more useful arm. 
  
Patey mastectomy: It is also a type of 
this, the entire breast including nipple a
removed with, pectoralis minor, followed by axillary block dissection. A 
complete axillary block dissection should include node clearance up to Level III
Scanlon’s operation: Is a modified Patey’soperation wherein instead
removing pectoralisminor, it is incised to approach the affected Level III lymph 
nodes 
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 modified radical mastectomy. In 
nd areola (simple mastectomy) are 
 
. 
 of 
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AXILLARY NODE DISSECTION: 
 
Right axillary clearance: (a)The lateral border of pectoralis major is 
defined and the fascia incised along its length to gain access into the axilla. (b) 
The axillary contents are retracted downwards and the fat over the axillary vein 
is carefully incised until it can be identified. (c) The apical division of fat and 
lymphatics is easier after the medial and posterior wall dissection has been 
completed. 
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 Radical mastectomy:  
 
In this operation, following structures are removed 
• Entire breast including nipple and areola, skin overlyingthe tumour along with 
fat, fascia and lymphatics. 
• Axillary block dissection, including complete clearance of axillary fat and up 
to Level III nodes clearance. 
• Sternocostal portion of pectoralis major, entire pectoralisminor, few fibres and 
aponeurosis of internal oblique, serratus anterior, latissimusdorsi and 
subscapularis. 
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Three important structures should be preserved 
• Axillary vein 
• Bell's nerve (long thoracic nerve which supplies serratusanterior) 
• Cephalic vein. 
Disadvantages of radical mastectomy 
• Mutilating surgery 
• Poor cosmetic results 
• Lymphoedema of arm 
• High morbidity rate 
  Modified radical mastectomy is more frequently done. 
In our study we proceeded with Modified Radical Mastectomy- 
Auchincloss method for operable carcinoma.  
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Adjuvant treatment—2 types 
A. Radiotherapy  
• Following either MRM or BCS, the residual disease is controlled by 
administering radiotherapy in a dose of 4.500-5,000 cGy to the breast over 5-6 
weeks. 
• In the absence of nodal involvement axilla may be spared radiation 
• If 4 or more nodes are involved, then the field of radiation should include 
supraclavicular and internal mammary chains. 
INDICATIONS FOR POSTOPERATIVE RADIOTHERAPY 
• Tumor margin is positive 
• Pectoralis major is involved 
• Inner quadrant tumor 
• High grade tumors 
• Axillary clearance not satisfactory 
• Breast conservative surgery 
• Tumor size more than 5 cm 
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B. Systemic therapy: 
I. Adjuvant chemotherapy 
 
 It should be considered in all cases of early breast cancerirrespective of 
menopausal status, hormone receptor status and nodal status. 
• 1st line agents: Cyclophosphamide, Adriamycin, 5-Fluorouracil (CAF). 
Because of cardiotoxicity of adriamycin, epirubicin is preferred as in FEC 
regimen. 
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The preferred regime is anthracyclines (adriamycin) which have a better 
response rate. Either CAF or FEC every 21 days x 6 cycles or at every 21 days x 
4 cycles or just Adriamycin with cyclophosphamide (AC). However; the CMF 
(Cyclophosphamide, Mitomycin, Fluorouracil) regimen still continues to be 
used widely due to economicalreasons. 
• 2nd line agents: Taxanes—Paclitaxel and Docetaxel 
• 3rd line: Gemcitabine 
Indication for adjuvant chemotherapy 
• Tumor> 1 cm 
• Tumor< 1 cm with ER -ve, HER-2 +ve, high grade. 
Adjuvant trastuzumab therapy: 
Trastuzumab: A monoclonal antibody against tyrosine kinasereceptor (HER-2 
receptor) is administered in patients with HER-2 +ve patients since it has been 
shown to improve disease free survival (DFS) by 50%, when it is combined with 
taxane-based chemotherapy. It potentiates effects of chemotherapy. 
Dose: Loading 4 mg/kg. 
Maintenance 2 mg/kg/ week for 1 year. 
 56 
 
II. Adjuvant hormonal therapy 
Hormonal therapy is administered to patient in whom the tumor expressed 
steroid hormone receptors, i.e. ER/ PR.Those who are negative for ER/PR,will 
not benefit from these drugs. 
 
The drugs are categorized as follows 
• 1st line—Anti-oestrogens—Tamoxifen.Commonly, Tamoxifen in a dose of 20 
mg is used for 5 years, to be started only after completion of chemotherapy. 
 • Raloxifene is an oral selective estrogen receptor modulator (SERM) that has 
oestrogenic actions on bone and antioestrogen actions on the uterus
It is used in the prevention of osteoporosis in postmenopausal women. Studies 
have proved that no specific advantage of raloxifene in the adjuvant treatment of 
breast cancer rather than established drugs such as tamoxifen.
• 2nd line—Aromato
oestrogens/steroids by blocking the aromatase enzyme which converts 
androstenedione to oestradiol in the adrenals. 
 
57 
se inhibitors. They prevent synthesis of endogenous 
 
 and breast. 
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They are: 1st generation:Aminoglutethimide and 2nd generation—Anastrozole, 
Letrozole, Exemestane given to postmenopausal patients. 
• Letrozole costlier than tamoxifen, reduces oestrogen levels by 98%, thus slows 
down oestrogen sensitive breast cancers.lt is given in the dose of 2.5 mg per day. 
Side effects:include vaginal bleeding, vaginal dryness, night sweats, hot flushes, 
osteoporosis, etc. Aromatase inhibitor in sequential use after Tamoxifen for a 
further period of 5 years has been shown to be beneficial. 
 
• 3rd line—Progestogens—Megestrol acetate 400 mg per day can be given 
• 4th line—Androgens such as Fluoxymestrone in the dose of 30 mg daily is 
another drug (Last 2 drugs are rarely given). 
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4.D-DIMER WITH OPERABLE CARCINOMA BREAST: REVIEW OF 
LITERATURE 
D-dimer, a biomarker of the fibrinolytic system is elevated in carcinoma patients 
as found in various studies. In our study pre-operative plasma d-dimer is 
evaluated by 
Particle Enhanced Imunoturbidimetry method, with biological reference interval  
Less than 0.5 ugm FEU/ml: negative 
More than 0.5 ugm FEU/ml: positive 
-LiW et al(2018) karger journal studied Prognostic role of pretreatment plasma 
d-dimer in patients with solid tumors, a systemic review and meta- analysis and 
concluded that there was strong evidence of elevated pre-treatment D-dimer 
associated with unfavorable overall survival and stages of the tumor.[11] 
-Cihan et al(2012) , in their study High D-dimer are associated with poor 
prognosis in cancer patients, concluded that higher d-dimer levels are associated 
with poor poorover all survival and increased mortality risk in cancer 
patients.[6] 
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-In bhavesh et al study showed statistically significant relationship between d-
dimer according to lymphovascular invasion and increase in tumor size, such 
that d-dimer has a possible role as prognostic factor in carcinoma breast.[12] 
-In ganpat et al study showed significant correlation between mean values of 
plasma d-dimer, tumor size, lymphovascular invasion, histological grade, 
advancing stage of the disease.[13] 
-In hudhaifah shaker et al study, plasma d-dimer correlated with lmphovasuclar 
invasion and tumor size statistically significant but not significant with hormone 
receptor status.[14] 
-In Blackwell et al study concluded a linear regression modeling showed 
relationship between the presence of lymphovascular invasion and elevated d-
dimer levels.[15] 
-In Rajendran et al study showed statistically significant relationship between 
values of d-dimer and lymphovascular invasion, number of nodes involved and 
advancing stage of carcinoma breast. No significance between d-dimer and 
increasing tumor size.[16] 
-In L.Y Dirix et al study, Plasma fibrin D-dimer levels correlate with tumour 
volume, progression rate and survival in patients with metastatic breast cancer. 
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Concluded that significant increased d-dimer levels as a predictor for rapid 
tumor growth, shorter survival in breast cancer patients.[6] 
-S, H., Sringeri  et al (2018) in their study showed that plasma D-Dimer levels 
were elevated in breast carcinoma patients. Increased D-Dimer levels are an 
important marker of clinical stage, lymphovascular invasion, lymph node 
involvement, and tumor metastasis.[17] 
-sapnapatel et al (2018) concluded that study showed that high plasma D-dimer 
levels can be used as a marker for lymph node involvement and higher 
histopathological grade. Due to the ease with which plasma D-dimer levels can 
be obtained and its cost effectiveness, quantitative D-dimer levels can be added 
as addition blood investigation for carcinoma breast patients[18]. 
-Malik Zeb Khan et al, in their study Fibrinogen  degradation products and d-
dimer in patients with breast carcinoma, concluded The levels of Fibrinogen 
Degradation Products and D-Dimers are elevated in breast carcinoma, especially 
in those with distant metastasis[19]. 
-Khangarot, Shyamveer Singh et al (2011) studied Correlation of D dimer and 
factor VIII levels with histopathology in patients with breast carcinoma and 
concluded that D-dimer and factor VIII may be used as yardstick for systemic 
adjuvant therapy in node negative < 1 cm breast cancer. D-dimer can be prove to 
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be a convenient, safe and easily available biomarker which can be combined 
with conventional sentinel node biopsy in clinically node negative breast cancer 
to assess metastatic disease in axilla and reduce false negative results[20]. 
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A DESCRIPTIVE STUDY OF: 
ANALYTICAL STUDY OF 
CORRELATION BETWEEN PLASMA 
D-DIMER LEVELS AND 
LYMPHOVASCULAR 
INVOLVEMENT IN OPERABLE 
CARCINOMA BREAST 
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5. MATERIALS AND METHOD 
STUDY DESIGN: 
Descriptive study 
PLACE OF STUDY: 
 Department of general surgery –Govt.Stanley medical college &hospital 
STUDY PERIOD: 8MONTHS 
february2018 to September 2018. 
PATIENT SELECTION: 
The patients admitted to the Stanley Hospital in Department of General Surgery 
with FNAC/TRUCUT proven operable carcinoma breast during the study 
period. 
INCLUSION CRITERIA: 
FNAC/Trucut proven carcinoma breast.                             
EXCLUSION CRITERIA: 
        Other malignancies  
        Coagulation and bleeding disorders  
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        Co-morbidities like myocardial infarction, cerebral vascular disease 
     Bilateral breast carcinoma  
     Recurrent breast carcinoma 
SAMPLE SIZE: 90Patients 
METHODOLOGY: 
- Ethical committee clearance 
- Informed consent 
- Pre-operative plasma D-dimer levels will be analyzed in operable Carcinoma 
Breast Pre operatively and TNM Staging will be done according to American 
Joint Committee on Cancer(AJCC).Modified radical mastectomy done for the 
following patients. 
Post operative HPE report for lymphovascular invasion, Stage of carcinoma 
breast  compared to d-dimer levels. 
D-DIMER: Normal  range<0.5ug FEU/ml 
During the study period out of 95 cases operated.90 cases taken for study 
purpose. Rest of the five cases did not come for reviewwith the histopathology 
report.Hence excluded from the study. 
 67 
 
6.OBSERVATION AND RESULTS 
STASTISTICAL ANALYSIS 
The collected data were analysed with IBM.SPSS statistics software 23.0 
Version.To describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and the mean & S.D 
were used for continuous variables. To find the significance between the 
bivariate samples in  Independent groups the Unpaired sample t-test was used. 
For the multivariate analysis the KruskalWalli's test followed by the Mann-
Whitney U test was used.To find the significance in categorical data Chi-Square 
test was used. In all the above statistical tools the probability value .05 is 
considered as significant level.     
  
AGE 
  Frequency Percent 
Valid Upto 40 yrs 18 20.0 
41 - 50 yrs 35 38.9 
51 - 60 yrs 30 33.3 
Above 60 yrs 7 7.8 
Total 90 100.0 
  
In our study out of 90 patients occurrence of carcinoma breast upto 40yrs was 18 
patients(20%), 41-50 years of age- 35patients(38.9%), 51-60years of age-30 
patients(33.3%), above 60years- 7patients(7.8%). 
  
 
STAGE OF CARCINOMA BREAST:
 
 
Stage 
  Frequency
Valid I 5 
II 52
III 33
Total 90
 
In our study out of 90 patients, stage I 
(57.8%), stage III- 33 patients (36.7%).
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 Percent 
5.6 
 57.8 
 36.7 
 100.0 
– 5patients (5.6%), stage II
 
 
- 52 patients 
  
LYMPHOVASCULAR INVASION:
  
Valid
 
In our study out of 90 operable carcinoma breast patients, post
Modified Radical Mastectomy histopathology report showed 74 patie
lymphovascular invasion present(82.2%), 16 patients with no lymphovascular 
invasion(17.8%). 
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lymphovascular invasion 
Frequency Percent 
 No 16 17.8 
Yes 74 82.2 
Total 90 100.0 
 
-operative 
nts with 
 Descriptives:
 
 
Descriptive Statistics
  N 
Age 90
d-dimer 90
Valid N 
(listwise) 
90
 
Ranks
Stage
d-
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Minimum Maximum Mean 
Std. 
Deviation
 35 75 49.41 8.399
 .10 1.24 .5678 .25568
        
 
 
 N 
Mean 
Rank 
dimer 1 5 18.80 
2 52 42.36 
3 33 54.50 
Total 90   
 
 
 
 
 
 Descriptives 
d-dimer 
  N 
I 5 
II 52
III 33
Total 90
 
Test Statisticsa,b 
  
Chi-Square 
Df 
Asymp. Sig. 
a. Kruskal Wallis Test
b. Grouping Variable: Stage
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Mean 
Std. 
Deviation Minimum Maximum
.30 .16 .10 .50
 .53 .24 .20 .90
 .66 .25 .22 1.24
 .57 .26 .10 1.24
d-dimer 
9.920 
2 
.007 
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Ranks 
Stage N 
Mean 
Rank 
Sum of 
Ranks 
d-dimer 1 5 15.20 76.00 
2 52 30.33 1577.00 
Total 57     
 
Test Statisticsa 
  d-dimer 
Mann-
Whitney 
U 
61.000 
Wilcoxon 
W 
76.000 
Z -1.951 
Asymp. 
Sig. (2-
tailed) 
.051 
Exact 
Sig. 
[2*(1-
tailed 
Sig.)] 
.051b 
a. Grouping Variable: Stage 
b. Not corrected for ties. 
 
Mann-Whitney Test 
Ranks 
Stage N 
Mean 
Rank 
Sum of 
Ranks 
d-dimer 1 5 6.60 33.00 
3 33 21.45 708.00 
Total 38     
 
 
 
 
 
 
 
 
 
 73 
 
Test Statisticsa 
  d-dimer 
Mann-
Whitney 
U 
18.000 
Wilcoxon 
W 
33.000 
Z -2.790 
Asymp. 
Sig. (2-
tailed) 
.005 
Exact 
Sig. 
[2*(1-
tailed 
Sig.)] 
.003b 
a. Grouping Variable: Stage 
b. Not corrected for ties. 
 
Mann-Whitney Test 
Ranks 
Stage N 
Mean 
Rank 
Sum of 
Ranks 
d-dimer 2 52 38.53 2003.50 
3 33 50.05 1651.50 
Total 85     
 
Test Statisticsa 
  d-dimer 
Mann-Whitney 
U 
625.500 
Wilcoxon W 2003.500 
Z -2.100 
Asymp. Sig. (2-
tailed) 
.036 
a. Grouping Variable: Stage 
 
 
 T-
Test 
Group Statistics
lymphovascular 
invasion 
d-
dimer 
Yes
No
 
Independent Samples Test 
  
Levene's Test for 
Equality of 
Variances 
F Sig. 
d-
dimer 
Equal 
variances 
assumed 
11.540 .001 
Equal 
variances 
not 
assumed 
    
 
 
74 
 
N Mean 
Std. 
Deviation 
 74 .63 .24 
 16 .28 .10 
t-test for Equality of Means 
T df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference
5.737 88 .000 .34696 .06048
9.441 58.270 .0005 .34696 .03675
Std. 
Error 
Mean 
.03 
.02 
 
 
95% interval of the 
difference 
Lower Upper 
 .22677 .46715 
 .27341 .42051 
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Crosstabs 
 
 
 
Stage * lymphovascular invasion Crosstabulation 
  lymphovascular 
invasion 
Total 
No Yes 
No Yes I 31.3%   
Stage 1 Count 5 0 5 II 68.8% 55.4% 
% 31.3% 0.0% 5.6% III   44.6% 
2 Count 11 41 52 
% 68.8% 55.4% 57.8% 
3 Count 0 33 33 
% 0.0% 44.6% 36.7% 
Total Count 16 74 90 
% 100.0% 100.0% 100.0% 
 
 
 
Chi-Square Tests 
  Value df 
Asymp. 
Sig. (2-
sided) 
Pearson 
Chi-Square 
30.666a 2 .0005 
Likelihood 
Ratio 
30.579 2 .000 
Linear-by-
Linear 
Association 
22.996 1 .000 
N of Valid 
Cases 
90     
a. 2 cells (33.3%) have expected count less 
than 5. The minimum expected count is .89. 
 
 
  
D-dimer being compared with stages of the Carcinoma breast using 
Krushal-Wallis test, results being No significance (p value >0.050) between d
dimer levels in stage I and stageII patients but highly significant (p value <0
between stage I and stage III and significant (0.01<p<0.050) between stage II 
and stage III. 
By using t-test lymphovascular invasion present in 74 patients had mean 
d-dimer value and standard deviation being 0.63 and 0.24 respectively and with 
no lymphovascular invasion d
significant (pvalue<0.0005)
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-dimer value being 0.10, being statically 
 
 
-
.01) 
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7.DISCUSSION 
Our study showed that maximum number operable carcinoma breast 
patients were stage II being 57.8%( 52 out of 90 patients) and lowest being stage 
I 5.6%(5 out of 90 patients. 
Lymphovascular invasion was found to be in 82.2%(74  out of 90 
patients) and with no lymphovascular invasion in 17.8% (16 out of 90 patients). 
In descriptive statistics, Minimum age of diagnosed carcinoma breast in 
our study was 35 years and maximum age being 75 years. 
 Minimum value of d-dimer was found to be 0.10ugFEU/ml and 
maximum valve being 1.24uFEU/ml with the mean value and standard deviation 
being 0.5678 and 0.25568 respectively 
D-dimer being compared with stages of the Carcinoma breast using 
Krushal-Wallis test, results being No significance (p value >0.050) between d-
dimer levels in stage I and stageII patients but highly significant (p value <0.01) 
between stage I and stage III and significant (0.01<p<0.050) between stage II 
and stage III. 
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In Blackwell et al study concluded a linear regression modeling showed 
relationship between the presence of lymphovascular invasion and elevated d-
dimer levels[15]. 
In Rajendran et al study showed statistically significant relationship 
between values of d-dimer and lymphovascular invasion, number of nodes 
involved and advancing stage of carcinoma breast. No significance between d-
dimer and increasing tumor size[16]. 
By using t-test lymphovascular invasion present in 74 patients had mean 
d-dimer value and standard deviation being 0.63 and 0.24 respectively and with 
no lymphovascular invasion d-dimer value being 0.10, being statically 
significant (pvalue<0.0005)      
In bhavesh et al study showed statistically significant relationship 
between d-dimer according to lymphovascular invasion and increase in tumor 
size, such that d-dimer has a possible role as prognostic factor in carcinoma 
breast[12]. 
In ganpat et al study showed significant correlation between mean values 
of plasma d-dimer, tumor size, lymphovascular invasion, histological grade, 
advancing stage of the disease[13]. 
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In hudhaifah shaker et al study, plasma d-dimer correlated with lmphovasuclar 
invasion and tumor size statistically significant but not significant with hormone 
receptor status[14]. 
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8.CONCLUSION 
Carcinoma breast requires prompt diagnosis and treatment to prevent 
cancer related deaths. Survival depends upon the stage of the disease at the time 
of diagnosis and lymph node status being an important prognostic factor[21]. 
Our study of  D-Dimer with lymphovascular invasion in operable 
carcinoma breast clearly shows d-dimer levels increased in carcinoma breast 
patients especially with advancing stage of the tumor. Increased d-dimer can be 
considered as a potential biomarker for tumor size, lymph node involvement and 
lymphovascular invasion and early tumor metastasis in operable carcinoma 
breast[12]. 
Since d-dimer is a safe, easily available predictive and convenient marker 
it can be viewed as a potential prognostic marker for operable carcinoma breast. 
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10.CLINICAL PERFORMA 
•NAME: 
•AGE: 
•SEX: 
•IP NO: 
•DIAGNOSIS 
-USG BREAST WITH AXILLA 
-FNAC/CORENEEDLE BIOPSY 
-USG ABDOMEN AND PELVIS/ XRAYS OF LONG BONES 
-CECT CHEST/ CECT ABDOMEN AND PELVIS/ BONE SCAN 
STAGE OF THE DIEASE: 
• PRE-OPERATIVE D-DIMER LEVEL 
•POST OPERATIVE HPE 
-LYMPHOVASCULAR INVASION 
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11. MASTER CHART 
 
s.no name age/f ipno. stage d-dimer (ugm feu/ml) lymphovascular invasion
1 vijaya 55 1843376 II 0.72 yes
2 parimala 38 1846918 II 0.22 no
3 saroja 62 1845719 III 0.8 yes
4 komala 60/f 1847534 II 0.6 yes
5 bhuvaneshwari 46 1847314 I 0.4 no
6 sugunya 54 1847685 III 0.9 yes
7 uma 43 1837157 III 0.66 yes
8 kanniyammal 58 1847283 III 0.8 yes
9 ayisha 37/f 1847283 II 0.3 no
10 malarvizhi 46 1857665 II 0.86 yes
11 lakshmi 65 1856038 III 0.74 yes
12 shanthi 49 1860412 III 0.66 yes
13 thulasi 63 1863108 II 0.38 yes
14 sundari 40 1864163 II 0.32 no
15 jaynathi 47 1844679 III 0.6 yes
16 kalaiselvi 57 1810041 II 0.2 yes
17 indumathi 45 1811488 III 0.56 yes
18 vijayalakshmi 43 1824061 II 0.48 yes
19 anjalai 39 1828646 II 0.22 no
20 banumathi 55 1829768 III 0.74 yes
21 vasantha 56 1822226 II 0.4 yes
22 revathy 40 1830553 II 0.2 no
23 rashitha 60 1836732 III 0.76 yes
24 mallika 50 1841404 II 0.8 yes
25 kannika 42 1841402 II 0.36 no
26 sumathi 35 1841393 III 0.82 yes
27 chinna ponnu 45 1839702 II 0.76 yes
28 kaveri 53 1843346 II 0.9 yes
29 pramila 42 1845011 II 0.66 yes
30 radha 55 1845055 III 1 yes
31 nivetha 40 1860112 II 0.8 yes
32 mohana 55 1800464 II 0.34 no
33 ponnuselvi 60 1801689 II 0.8 yes
34 chandra 38 1806322 II 0.56 yes
35 pradeepa 52 1812412 II 0.2 no
36 durga devi 49 1821934 III 0.74 yes
37 uma maheshwari 56 1825984 II 0.24 no
38 amirthavalli 40 1863676 II 0.8 yes
39 kavitha 43 1812421 III 0.3 yes
40 krishnaveni 60 1822999 II 0.36 no
41 velazhagi 45 1822944 II 0.34 yes
42 muthulakshmi 48 1823618 III 0.48 yes
43 soundarya 50 1828371 II 0.3 yes
44 lakshmi priya 40 1828367 III 0.38 yes
45 hemalatha 55 1829780 II 0.26 no
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46 nagajothi 38 1829447 III 0.36 yes
47 navaj 40 1831528 II 0.2 yes
48 saraswathy 45 1831432 III 0.46 yes
49 kavya 58 1831931 II 0.2 yes
50 baby 41 1833149 III 0.24 yes
51 saranya 47 1832428 II 0.8 yes
52 janani 49 1884817 III 0.82 yes
53 nandhimi 40 1808029 II 0.74 yes
54 dhanasundari 65 1809232 II 0.76 yes
55 sathyavani 50 1853681 III 1.22 yes
56 gajalakshmi 57 1810534 II 0.84 yes
57 ganga 42 1820225 II 0.56 yes
58 rita 66 1824000 I 0.1 no
59 senthamari 54 1858331 III 1.24 yes
60 yamuna 59 1831536 II 0.84 yes
61 nagalakshmi 75 1841407 II 0.54 yes
62 neelavani 45 1828649 III 0.8 yes
63 malliga 60 1845980 II 0.56 yes
64 mala 55 1807964 I 0.3 no
65 rajeshwari 39 1810753 III 0.4 yes
66 vijaya 35 1835405 II 0.38 yes
67 rajalakshmi 54 1810724 II 0.48 yes
68 ponni 46 1812197 III 0.36 yes
69 angammal 50 1819207 II 0.2 yes
70 pachaimaal 55 1819195 III 0.22 yes
71 muthurani 48 1819356 II 0.34 yes
72 tamilselvi 55 1820236 II 0.2 yes
73 mukkammal 45 180083 II 0.7 yes
74 mumtaz begum 45 1845694 III 0.66 yes
75 sowkath 46 1800753 II 0.64 yes
76 devaki 38 1809788 III 0.9 yes
77 ethiyammal 38 1819986 I 0.2 no
78 kalyani 50 1819488 II 0.6 yes
79 adhilakshmi 53 1812236 III 0.72 yes
80 radhika 47 1800541 II 0.9 yes
81 rani 47 1821231 II 0.86 yes
82 nadhiya 62 1822203 II 0.6 yes
83 maheshwari 42 1832042 III 0.52 yes
84 shantha 45 1825007 II 0.76 yes
85 jayantha 59 1824960 III 0.66 yes
86 rose 57 1825452 II 0.74 yes
87 kala 40 1826165 I 0.5 no
88 marilakshmi 54 1829469 III 0.6 yes
89 sangeetha 45 1835026 II 0.86 yes
90 manonmani 55 1877810 III 0.8 yes
